Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISB 2001 in Relapsed/Refractory Multiple Myeloma
NCT05862012Phase 1Recruiting
- Sponsor
- Ichnos Sciences Inc.
- Start
- Nov 2023
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of ISB 2001 in multiple myeloma (MM) (2 arms), sponsored by Ichnos Sciences Inc. Primary endpoints: Frequency and Severity Of Treatment-Emergent Adverse Events at 18 months and Number of Dose-Limiting Toxicities at 28 days. Started Nov 2023; status: recruiting.
02
Drugs
ISB 2001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05862012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862012.